TEVA Q1 2025 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B+1.9% YoY

Gross Profit

$1.9B48.2% margin

Operating Income

$519M13.3% margin

Net Income

$214M5.5% margin

EPS (Diluted)

$0.18

QoQ Revenue Growth

-8.0%

Cash Flow

Operating Cash Flow

-$105M

Free Cash Flow

-$232M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$38.4B

Total Liabilities

$32.1B

Stockholders' Equity

$6.3B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$3.8B	+1.9%
Gross Profit	$1.9B	$1.8B	+6.0%
Operating Income	$519M	-$218M	+338.1%
Net Income	$214M	-$139M	+254.0%

Revenue Segments

Product

$3.4B87%

Distribution Service

$384M10%

Product and Service, Other

$76M2%

License

$36M1%

Geographic Segments

North America Segment

$1.9B52%

Europe Segment

$1.2B32%

International Markets

$582M16%